GSTM1 and glycogen storage disease VI: Given the positive effect of ziltivekimab on Hb levels, it is plausible that ESA requirements could decrease or stop, as was observed in the phase 1/2 study.8 The relatively short duration of the RESCUE trial (12 weeks), owing to early termination because of the coronavirus disease 2019 pandemic, was an additional limitation of the analyses.